The founding team transfered the top-tier technology and more than 20 years of scientific research experience in metabolomics from Germany to China. Metanotitia has been innovating and practicing in the chinese market since its establishment in 2018 in Shenzhen, China.
We’ve been perfecting workflows to drive clinical and operational efficiency. Our proprietaryProfMet platform is the solution to large-scale metabolomics studies, providing standardized, high-throughput, deep-coverage data with a self-built metabolomics MS and MS/MS library of over 8000 standards. Our platform's capabilities can be applied in screening, diagnosis, prognosis, prediction, and monitoring throughout the continuity of care in various indications.
In large-scale metabolomics researches, it has been an industrial pain point of how to remove the systematic error that imposes non-negligible impacts on the analysis results. Metanotitia’s comprehensive solution can remove noise and systematic error while preserving biological differences, thanks to its advanced quality control system and state-of-the-arts data processing algorithms.